Hormonal
Central administration of Neuropeptide Y (NPY) acts as a potent orexigenic signal that stimulates food intake, specifically increasing carbohydrate preference, reducing the latency to eat, and delaying satiety to augment meal size.
Neuropeptide Y (NPY) is a brain chemical that strongly drives hunger, specifically for carbohydrates. It works by making you start eating sooner, motivating you to work harder for food, and making you feel full later than usual, leading to larger meals. This is a central brain mechanism, not triggered by eating NPY from food.
Neuropeptide Y (NPY) is one the most potent orexigenic peptides found in the brain. It stimulates food intake with a preferential effect on carbohydrate intake. It decreases latency to eat, increases motivation to eat and delays satiety by augmenting meal size.
Why this rating
The paper is a comprehensive review of decades of consistent findings across multiple species and experimental paradigms.
Source
Neuropeptide Y in normal eating and in genetic and dietary-induced obesity
Bernard Beck · Philosophical Transactions of the Royal Society B Biological Sciences · 2006
DOI 10.1098/rstb.2006.1855
More from this paper
- Fasting and energy restriction upregulate the NPY system (increasing mRNA and peptide content in the arcuate nucleus), while refeeding and high-fat/high-energy diets tend to downregulate or decrease NPY expression as a counter-regulatory mechanism.Strong
- The orexigenic effects of Neuropeptide Y are mediated primarily through Y1 and Y5 receptors, with Y1 playing a dominant role in appetitive behavior and Y5 in consummatory behavior.Good
- Genetic obesity models with leptin signaling failure (e.g., Zucker rats, ob/ob mice) exhibit increased NPY mRNA and peptide levels, whereas other genetic obesity models (e.g., agouti, tubby mice) show decreased NPY in the arcuate nucleus but increased expression in the dorsomedial nucleus.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →